Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab and Rituximab in First-line Follicular Lymphoma
NCT05783609Phase 2Recruiting
- Start
- Jun 2023
- Primary completion
- Feb 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of epcoritamab in follicular lymphoma (FL) (2 arms). Primary endpoint: End of Treatment Complete Metabolic Response Rate up to 267 days. Started Jun 2023; status: recruiting.
02
Drugs
epcoritamab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT05783609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05783609.